Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

March 31, 2026

Conditions
Mild Cognitive ImpairmentAlzheimer's Disease
Interventions
DRUG

Centella asiatica product

A sachet of powdered product containing 4 g of a dried hot water extract of Centella asiatica as the active ingredient, combined with inactive ingredients (excipients) for color and taste dissolved in 10 oz of warm or room temperature water and consumed orally.

DRUG

Placebo

A sachet of powdered inactive ingredients (excipients) for color and taste identical in volume to those found in the active arm (CAP) dissolved in 10 oz of warm or room temperature water and consumed orally.

Trial Locations (1)

97239

RECRUITING

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

Oregon Health and Science University

OTHER